Please note that masks must still be worn within NYOH practices regardless of vaccination status.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

Ph3 Abem HR+ HER2+ BC

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (I3Y-MC-JPCW)

Disease Types: Breast,&nbs

Available at: {clinical_trial_location backspace="7"}Ph3 Abem HR+ HER2+ BC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}